Paul Hud­son spells out new $6.15B tech­nol­o­gy play as Sanofi goes drug hunt­ing in on­col­o­gy, im­munol­o­gy

Sanofi now has an­oth­er pow­er­ful weapon in its ar­se­nal to de­ploy against a wide va­ri­ety of tar­gets across on­col­o­gy, im­munol­o­gy and in­flam­ma­tion.

Ty­ing the knot with IGM Bio­sciences, the French phar­ma gi­ant is plop­ping down a siz­able, $150 mil­lion up­front to ac­cess its IgM an­ti­body tech­nol­o­gy plat­form — with an eye firm­ly on ag­o­nists rather than in­hibitors — while lay­ing out $6 bil­lion in po­ten­tial mile­stones and op­por­tu­ni­ties for 50:50 prof­it-shar­ing arrange­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER